The assessment of Crohn's disease activity through endoscopy is a cornerstone of both clinical management and research. In The Lancet Gastroenterology & Hepatology, Christopher Ma and colleagues ...

Within weeks of treating patients with CER-1236, the company hopes to start learning about its safety profile and gauge efficacy markers.

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...